Latest Regulatory News

Page 375 of 753
MIXI Australia has secured majority voting power in PointsBet, pushing the takeover offer deadline to mid-September and setting the stage for full control.
Claire Turing
Claire Turing
29 Aug 2025
Platformo Ltd reported a 38% revenue increase driven by its Malaysian software arm Biztrak, alongside a modest improvement in its half-year loss. The company continues to navigate regulatory shifts and product enhancements in a competitive software market.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Zelira Therapeutics reported a significantly reduced loss of AUD 3.85 million for FY25, driven by clinical progress and strategic funding for its HOPE® cannabinoid medicines. The company also expanded its patent portfolio and commercial footprint across key markets.
Ada Torres
Ada Torres
29 Aug 2025
Paradigm Biopharmaceuticals marked FY25 with the launch of its global Phase 3 trial for its osteoarthritis drug iPPS, backed by strong FDA protocol approval and a $41 million funding facility. The company also broadened its pipeline with the acquisition of Pentacoxib™, targeting early-stage OA.
Ada Torres
Ada Torres
29 Aug 2025
Skin Elements Limited reported a 13% revenue increase and a 20% reduction in net loss for FY2025, as it progresses commercial roll-out of its natural biotech products including ECO-Nurture and SuprCuvr.
Ada Torres
Ada Torres
29 Aug 2025
Saferoads Holdings Limited reported a net profit of $4.35 million for FY2025, driven largely by a $5.27 million gain from the sale of its Road Safety Rental business. Continuing operations showed a modest loss amid a 14% revenue decline.
Victor Sage
Victor Sage
29 Aug 2025
Neurotech International reported a 23% revenue drop and a doubling of its net loss to $10.6 million for FY25, driven by reduced R&D grants and high development costs. Despite financial pressures, the company marked significant clinical and regulatory progress for its NTI164 cannabinoid therapy.
Ada Torres
Ada Torres
29 Aug 2025
OncoSil Medical reported a $15.1 million loss for FY25 amid strong revenue growth and significant regulatory milestones, supported by over $14 million in capital raises to fuel its global expansion.
Ada Torres
Ada Torres
29 Aug 2025
Orthocell Ltd reported a record $9.23 million revenue for FY25, driven by strong sales of its nerve repair and dental products, alongside securing US FDA clearance for its flagship nerve repair device Remplir. The company is poised for accelerated growth as it expands its global commercial footprint.
Ada Torres
Ada Torres
29 Aug 2025
Cann Group Limited reported a 34% rise in dried flower production and doubled Botanitech brand flower sales in FY25, while cutting operating expenses by 35%. The company is targeting an EBITDA-positive FY26 amid ongoing debt restructuring.
Ada Torres
Ada Torres
29 Aug 2025
Bioxyne Limited delivered a record FY25 with $30.4 million revenue, driven by Australian market growth and new European contracts. The company projects revenue up to $75 million in FY26, fueled by expanded production and international market entries.
Ada Torres
Ada Torres
29 Aug 2025
Echo IQ Limited reported a sharp increase in losses for FY25 despite revenue growth, while securing FDA clearance and expanding its AI-driven cardiology platform across major US networks.
Ada Torres
Ada Torres
29 Aug 2025